H2-antagonists in the treatment of colon and breast cancer.
Several clinical trials have now been carried out with histamine type 2 receptor antagonists in cancer patients often as an adjunct to surgical resection of the primary tumour While promising results have been obtained in some groups of patients with gastrointestinal cancer, with increased survival and evidence of increased immunological recognition of tumour, results are less encouraging for breast cancer. This may be due to differences in the levels of histamine or the role of histamine in growth of these different tumour types.
Bolton
E
E
University of New South Wales, Department of Surgery, St George Hospital, Sydney, Australia.
King
J
J
Morris
D L
DL
D000276:Adjuvants, Immunologic; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007111:Immunity, Cellular / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating; D051379:Mice; D008819:Mice, Nude; D016032:Randomized Controlled Trials as Topic; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D006635:Histamine H2 Antagonists